Treatment-shift from primary surgery to radiotherapy for stage T1b cervical cancer in the United States
Geburtshilfe und Frauenheilkunde · 01.10.2024 · 84 (10) · e161
DOI: 10.1055/s-0044-1790809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.10.2024. Verfasst von M. Klar und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
To assess temporal trends of primary treatment approach for stage T1b cervical cancer in the United States.
Methods
This retrospective cohort study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Study population was 11,706 patients with AJCC T1b/N0-1/M0 cervical cancer who received primary anti-cancer treatment either with hysterectomy or definitive radiotherapy without hysterectomy from 2004-2021. Linear segmented regression with log-transformation was used to assess primary treatment per one-year increments. Exploratory analysis included survival association for primary therapy.
Results
The most frequent tumor size was ≤2cm ( n =4,763, 40.7%), followed by 2.1-4cm ( n =4,203, 35.9%) and >4cm ( n =2,740, 23.4%). Among node-metastasis cases, use of primary radiotherapy increased in all three size groups from 2004-2021 (≤2cm, 13.1% to 41.1%; 2.1-4cm, 15.2% to 52.2%; >4cm, 36.7% to 85.2%, all, P 4cm from 2010-2021 (44.6% to 68.8%, P=.002) whereas primary hysterectomy remained the majority in size ≤2cm (93.5% to 89.4%) and 2.1-4cm (83.4% to 81.5%) groups (both, P >.05). Primary hysterectomy was associated with improved survival in all subgroups except for node-metastatic size >4cm where these two modalities had comparable survival.
Conclusion
The results of current population-based assessments suggest that primary treatment for stage T1b cervical cancer is gradually shifting from hysterectomy to radiotherapy in the United States when nodes are involved despite smaller tumor size of ≤2cm or 2.1-4cm. This real-world practice data suggests possible prognostic role of primary hysterectomy in tumor size ≤4cm even nodes are involved, warranting further evaluation. Publication History Article published online: 01 October 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Klar, M., Lee, M. W., Yu, E., Matsuzaki, S., & Matsuo, K. (2024). Treatment-shift from primary surgery to radiotherapy for stage T1b cervical cancer in the United States. Geburtshilfe und Frauenheilkunde, 84(10), e161. https://doi.org/10.1055/s-0044-1790809
Vancouver
Klar M, Lee MW, Yu E, Matsuzaki S, Matsuo K. Treatment-shift from primary surgery to radiotherapy for stage T1b cervical cancer in the United States. Geburtshilfe und Frauenheilkunde. 2024;84(10):e161. doi:10.1055/s-0044-1790809
BibTeX
@article{Klar2024,
author = {Klar, M. and Lee, M. W. and Yu, E. and Matsuzaki, S. and Matsuo, K.},
title = {Treatment-shift from primary surgery to radiotherapy for stage T1b cervical cancer in the United States},
journal = {Geburtshilfe und Frauenheilkunde},
year = {2024},
volume = {84},
number = {10},
pages = {e161},
doi = {10.1055/s-0044-1790809}
}
EUVIMED